Navigation Links
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Date:2/9/2009

ed by the NIH-funded Microbicide Trials Network (MTN) at seven clinical centers in Malawi, Zimbabwe, South Africa, Zambia, and the United States.

The trial was initiated in February 2005 and enrolled approximately 3,100 eligible, HIV-uninfected women, all of whom provided written informed consent. Enrolled participants were randomly assigned to one of four arms: PRO 2000 gel (0.5% strength), BufferGel, a placebo gel, or no gel. Women enrolled in the three gel arms were asked to apply the assigned study product vaginally up to one hour before each act of sexual intercourse. The gel arms were double-blinded so that neither the participant nor the study staff knew the identity of the assigned study product. Women in all four arms received a standard-of-care HIV prevention package, which included free male condoms, risk-reduction counseling, and treatment of sexually transmitted infections. Participants were followed for 12-30 months (20 months on average), depending on when they entered the study.

A total of 194 new HIV infections occurred among study participants over the course of the trial. Of these, 36 occurred in the PRO 2000 arm, 54 in the BufferGel arm, 51 in the placebo arm, and 53 in the no-gel arm. Based on these data, PRO 2000 was 30 percent effective (approximately 33 percent effectiveness would have been considered statistically significant). The adverse event profile was similar in all four arms, indicating that 0.5% PRO 2000 is safe for vaginal use. A full analysis of the trial data is underway.

The study was conducted in communities where the background rate of HIV infection is high. Participants who became infected with HIV during the trial were referred to local HIV care and support services. Where possible, infected participants were invited to participate in Microbicide Trials Network (MTN) 015, a clinical study examining the nature of HIV progression and treatment response in HIV-positive
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
4. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
5. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
6. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
7. Indevus Announces Submission of New Drug Application
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  In recognition of the increased risks that ... flu, pneumonia, shingles and other illnesses, CVS/pharmacy ® ... to be Senior Vaccination Month. Because people,s immune ... that adults ages 65 years and older stay ... and MinuteClinic nurse practitioners and physician assistants will ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. (OTCQB: ... that merged with MabVax Therapeutics, Inc. on July ... progress related to the development of its lead ... recovered using the Company,s internally developed antibody discovery ... for multiple antibody based therapeutic and diagnostic products ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
... ROCKVILLE, Md. , Jan. 28 A ... benefits and risks of implantable cardioverter defibrillators (ICDs) in patients ... by HHS, Agency for Healthcare Research and Quality and the ... project is being conducted in cooperation with the National Heart, ...
... BOCA RATON, Fla. , Jan. 28 ... leader in portable electronic medical records management, today announced that ...  The companies will collaborate on initiatives directed to U.S. seniors ... solution. , The Senior Site, Inc. caters to an extremely ...
Cached Medicine Technology:AHRQ and American College of Cardiology Collaborate On Study of Implantable Cardioverter Defibrillators 2MedeFile Makes Strides with the Senior Market 2MedeFile Makes Strides with the Senior Market 3MedeFile Makes Strides with the Senior Market 4MedeFile Makes Strides with the Senior Market 5
(Date:8/28/2014)... August 28, 2014 Gurnick Academy of ... Technology program is re-accredited for the 5 years of ... Imaging Technologists (ARMRIT). , “We are very proud ... improving our program to make sure we provide the ... of interest in MRI field nowadays and I look ...
(Date:8/28/2014)... Amy Norton HealthDay Reporter ... have found that sending electrical currents through the scalp to ... for up to a day. In a small study ... to fire up certain networks involved in memory. That, in ... apparent 24 hours after the brain stimulation. During TMS, ...
(Date:8/28/2014)... "stuck fermentation," when yeast that should be busily converting ... down, leaving the remaining sugar to instead be consumed ... team of researchers including UC Davis yeast geneticist Linda ... problem. Working through a prion -- an abnormally ... enables bacteria in fermenting wine to switch yeast from ...
(Date:8/28/2014)... August 28, 2014 Data from the ... that while most hospitals utilize a basic electronic health ... information technology is still a challenge. , This ... August issue of Health Affairs , and is co-authored ... Care Data Center, as well as Chantal Worzala, director ...
(Date:8/28/2014)... Tenn. The New England Journal of Medicine ... clinical trial of a drug shown to safely reduce ... volunteers intranasally infected with respiratory syncytial virus (RSV). ... of Tennessee Health Science Center researcher Infectious Disease Specialist ... , RSV is the most common cause ...
Breaking Medicine News(10 mins):Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:DeVincenzo study breakthrough in RSV research 2
... is serving up a surprise not only for tomato lovers ... rod-shaped bacterium that causes misery for millions of people. , ... PloS One , researchers say they,ve identified a molecular trick ... from the University of Rochester Medical Center has identified a ...
... has entered,into a binding agreement to purchase the ... MSC, which previously consisted of two,distinct units -- ... brand and,all employees, products and services not associated ... ESRX ) is one of the largest ...
... days to try to resolve remaining issues, TORONTO, ... PMD; Amex: PME) today announced that the Company has ... (FDA) in an,effort to resolve the outstanding issues associated ... test. Over the,next 60 days PreMD and the FDA ...
... research shows , , FRIDAY, June 13 (HealthDay News) -- ... the morning may help ease some stresses you might ... rats inhaled the aroma of roasted coffee beans, a ... proteins with healthful antioxidant activity, the researchers reported. ...
... June 13 The Blinded,American Veterans Foundation (BAVF), at ... Maryland State Delegate Sheila Hixson., "We,re honored to ... of Maryland,s District 20 and to the entire State ... MD. "Her,tireless efforts as a legislator and community activist ...
... more reliable detection of Chlamydia trachomatis, the most ... disease in Europe., PLEASANTON, Calif., June 13 ... Chlamydia trachomatis has received CE Mark,certification, allowing it to ... is designed with a dual target approach to help ...
Cached Medicine News:Health News:Salmonella: Trickier than we imagined 2Health News:Salmonella: Trickier than we imagined 3Health News:Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 2Health News:Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 3Health News:PreMD Reports Further Positive Meetings with the FDA 2Health News:Coffee Beans May Be Newest Stress-Buster 2Health News:Coffee Beans May Be Newest Stress-Buster 3Health News:Blinded Vets Foundation to Honor Maryland State Delegate Sheila Hixson 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3
Stryker bariatric laparoscopes set the standard in picture quality....
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
Compact, economical Bactron II anaerobic environment system with air lock, workspace and a 200 plate capacity incubator delivers optimum productivity in a compact space....
... Bactron I is an ... designed for use by smaller ... as an economical set-up station ... quality features of other Bactron ...
Medicine Products: